Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway

Assessments of prostate cancer cell functions highlight differences between a pan‐PI3K/mTOR inhibitor, gedatolisib, and single‐node inhibitors of the PI3K/AKT/mTOR pathway

Metastatic castration‐resistant prostate cancer (mCRPC) is characterized by loss of androgen receptor (AR) sensitivity and oncogenic activation of the PI3K/AKT/mTOR (PAM) pathway. Loss of the PI3K regulator PTEN is frequent during prostate cancer (PC) initiation, progression, and therapeutic resista...

Full description

Saved in:
Bibliographic Details
Main Authors: Adrish Sen, Salmaan Khan, Stefano Rossetti, Aaron Broege, Ian MacNeil, Ann DeLaForest, Jhomary Molden, Laura Davis, Charles Iversrud, Megan Seibel, Ross Kopher, Stephen Schulz, Lance Laing
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Molecular Oncology
Subjects:
gedatolisib
inhibitors
PI3K/AKT/mTOR pathway
prostate cancer
Online Access:https://doi.org/10.1002/1878-0261.13703
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items